NICE approves Bravtovi and Mektovi combination therapy as treatment options for specific types of melanoma patients

recently, the National Institutes of Health and Clinical Optimization (NICE) approved Pierre Fabre's Bravtovi and Mektovi combination therapy as a treatment option for specific types of melanoma patientsBraftoviBraftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor, and Mektovi (binimetinib) is an oral small molecule MEK inhibitor that specifically targets key enzymes in the MAPK signaling pathwayNICE points out that this combination of therapies is suitable for adult patients with BRAF V600 mutation-positive melanoma, which cannot be surgically removed or has spread to other organs nearbyTheapproval of the Braftovi-Mektovi combination is based on the results of phase III clinical studies in COLUMBUSThe data showed that the non-progressive lifetime of the Braftovi-Mektovi combination was doubled compared to the Roche late-stage melanoma drug Zelboraf (vemurafenib, Verofovini) (median PFS: 14.9 months vs 7.3 months, HR s.54,95%CI: 0.41-0.71, p.0001)the study, only 5% of patients in the Braftovi-Mektovi group stopped treatment for adverse reactions, and the most common adverse reactions in the group were fatigue, nausea, diarrhea, vomiting, abdominal pain and joint painData from the Total Lifetime (OS)Analysis(http://data in the COLUMBUS study show that the Braftovi-Mektovi program significantly reduced the risk of death compared to Zelboraf (960mg, once a day) (HR -0.61, 95% CI: 0.47-0.79, p 0.0001: The bit OS in the Zelboraf single-drug group is 16.9 months, and the bit OS in the Braftovi-Mektovi scheme group is 33.6 monthsThese positive data further enhance the clinical evidence of BRAF/MEK inhibitor combination therapyBraftovi and Mektovi were developed by(http://, the american bio
pharmaceutical (http:// company, and Pierre Fabre of France authorized the acquisition of the two products
(http:// exclusive commercialization rights in all other countries and regions except the United States, Canada, Israel, Japan, South Korea, including Europe, Latin America and Asia (except Japan and South Korea) Array retains exclusive rights to two products in the United States and Canada, Israeli pharmaceutical company Medison authorizes the exclusive commercialization rights of these two products in Israel, and Ono Pharmaceuticals authorizes the development and commercialization rights of these two products in Japan and South Korea